Yeztugo Patent Expiration

Yeztugo is a drug owned by Gilead Sciences Inc. It is protected by 4 US drug patents filed in 2025 out of which none have expired yet. Yeztugo's patents will be open to challenges from 22 December, 2026. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 25, 2040. Details of Yeztugo's patents and their expiration are given in the table below.

Filter patents by

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US11267799 Solid forms of an HIV capsid inhibitor
Aug, 2038

(12 years from now)

Active
US10071985 Therapeutic compounds
Aug, 2037

(11 years from now)

Active
US9951043 Therapeutic compounds
Feb, 2034

(8 years from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11807625 NA
Nov, 2040

(15 years from now)

Active


FDA has granted several exclusivities to Yeztugo. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Yeztugo, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Yeztugo.

Exclusivity Information

Yeztugo holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Yeztugo's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2027
New Product(NP) Jun 18, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Yeztugo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Yeztugo's family patents as well as insights into ongoing legal events on those patents.

Yeztugo's Family Patents

Yeztugo has patent protection in a total of 43 countries. It's US patent count contributes only to 12.5% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Yeztugo.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Yeztugo's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 25, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Yeztugo Generics:

There are no approved generic versions for Yeztugo as of now.

Alternative Brands for Yeztugo

There are several other brand drugs using the same active ingredient (Lenacapavir Sodium) as Yeztugo. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Gilead Sciences Inc
Sunlenca






About Yeztugo

Yeztugo is a drug owned by Gilead Sciences Inc. Yeztugo uses Lenacapavir Sodium as an active ingredient. Yeztugo was launched by Gilead Sciences Inc in 2025.

Approval Date:

Yeztugo was approved by FDA for market use on 18 June, 2025.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Yeztugo is 18 June, 2025, its NCE-1 date is estimated to be 22 December, 2026.

Active Ingredient:

Yeztugo uses Lenacapavir Sodium as the active ingredient. Check out other Drugs and Companies using Lenacapavir Sodium ingredient

Dosage:

Yeztugo is available in the following dosage forms - solution form for subcutaneous use, tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) SOLUTION Prescription SUBCUTANEOUS
EQ 300MG BASE TABLET Prescription ORAL